hydroxychloroquine has been researched along with Koch's Disease in 3 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is no consensus on whether it is safe to re-administer tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) flared after withdrawal of TNFα inhibitors due to active tuberculosis (TB)." | 1.40 | Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy. ( Ju, JH; Kwok, SK; Park, KS; Park, SH; Suh, YS; Yoon, CH, 2014) |
| "Tuberculosis is known to induce and exacerbate SLE and it becomes quite difficult to diagnose tuberculosis in this setting, owing to a similar, overlapping presentation of tuberculosis and SLE." | 1.39 | Disseminated tuberculosis in a patient with antinuclear antibody-negative systemic lupus erythematosus: a rare association. ( Aggarwal, P; Dev, N; Kumar, G; Kumar, N, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Tadolini, M | 1 |
| Codecasa, LR | 1 |
| García-García, JM | 1 |
| Blanc, FX | 1 |
| Borisov, S | 1 |
| Alffenaar, JW | 1 |
| Andréjak, C | 1 |
| Bachez, P | 1 |
| Bart, PA | 1 |
| Belilovski, E | 1 |
| Cardoso-Landivar, J | 1 |
| Centis, R | 1 |
| D'Ambrosio, L | 1 |
| Luiza De Souza-Galvão, M | 1 |
| Dominguez-Castellano, A | 1 |
| Dourmane, S | 1 |
| Fréchet Jachym, M | 1 |
| Froissart, A | 1 |
| Giacomet, V | 1 |
| Goletti, D | 1 |
| Grard, S | 1 |
| Gualano, G | 1 |
| Izadifar, A | 1 |
| Le Du, D | 1 |
| Marín Royo, M | 1 |
| Mazza-Stalder, J | 1 |
| Motta, I | 1 |
| Ong, CWM | 1 |
| Palmieri, F | 1 |
| Rivière, F | 1 |
| Rodrigo, T | 1 |
| Silva, DR | 1 |
| Sánchez-Montalvá, A | 1 |
| Saporiti, M | 1 |
| Scarpellini, P | 1 |
| Schlemmer, F | 1 |
| Spanevello, A | 1 |
| Sumarokova, E | 1 |
| Tabernero, E | 1 |
| Tambyah, PA | 1 |
| Tiberi, S | 1 |
| Torre, A | 1 |
| Visca, D | 1 |
| Zabaleta Murguiondo, M | 1 |
| Sotgiu, G | 1 |
| Migliori, GB | 1 |
| Suh, YS | 1 |
| Kwok, SK | 1 |
| Ju, JH | 1 |
| Park, KS | 1 |
| Park, SH | 1 |
| Yoon, CH | 1 |
| Kumar, N | 1 |
| Aggarwal, P | 1 |
| Dev, N | 1 |
| Kumar, G | 1 |
3 other studies available for hydroxychloroquine and Koch's Disease
| Article | Year |
|---|---|
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
Topics: Adult; Aged; Antitubercular Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Labora | 2020 |
Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies | 2014 |
Disseminated tuberculosis in a patient with antinuclear antibody-negative systemic lupus erythematosus: a rare association.
Topics: Adult; Antibodies, Antinuclear; Antirheumatic Agents; Antitubercular Agents; Female; Humans; Hydroxy | 2013 |